FDA Approves Remibrutinib for Symptomatic Dermographism

The FDA has approved remibrutinib, an oral, highly selective Bruton's tyrosine kinase inhibitor (BTKi), for adults with symptomatic dermographism (SD) and chronic spontaneous urticaria (CSU) that are inadequately controlled by H1 antihistamines. The approval for the SD indication was announced today.